Literature DB >> 20030241

[Clinical overview of neuromyelitis optica].

Brian G Weinshenker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20030241     DOI： 10.5692/clinicalneurol.49.894

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN： 0009-918X


× No keyword cloud information.
  3 in total

1.  Illuminating neuromyelitis optica pathogenesis.

Authors:  Richard M Ransohoff
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

2.  Bevacizumab is safe in acute relapses of neuromyelitis optica.

Authors:  Maureen A Mealy; Kyong Shin; Gareth John; Michael Levy
Journal:  Clin Exp Neuroimmunol       Date:  2015-08-24

3.  Updated diagnostic criteria for neuromyelitis optica spectrum disorder: Similar outcomes of previously separate cohorts.

Authors:  M McCreary; M A Mealy; D M Wingerchuk; M Levy; A DeSena; B M Greenberg
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-12-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.